Abstract: Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(?O)H, C(?O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substit

Abstract: We have found anti-inflammatory activity in the ecteinascidin compounds. Such compounds have been widely described, and may have the following general formula (I), wherein: R5 is OH, alkoxy or alkanoyloxy; R6 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R12 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R16 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R17 is OH, alkoxy or alkanoyloxy; R18 is OH, alkoxy or alkanoyloxy; R21 is H, OH, CN or another nucleophilic group; and Ra is hydrogen and Rb is optionally substituted amino, or Ra with Rb form a carbonyl function ?O, or Ra, Rb and the carbon to which they are attached form a tetrahydroisoquinoline group.

Abstract: Compounds of general formula (I), wherein R1, R2, R3, R4, R5, R6 and Y are as defined, and X group is O, S(O)m or NR; are of use in the treatment of cancer.

Abstract: Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction.

Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins.

Abstract: A gene cluster has open reading frames which encode polypeptides sufficient to direct the synthesis of a safracin molecule.

Abstract: New lamellarins are provided of the general formula III or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof

Abstract: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.

Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.

Abstract: Compounds of the general formula (I) or pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(=O)H, C(=O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substitut

Abstract: Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease such as psoriasis while avoiding toxicity and leading to clinical improvement.

Abstract: We have found anti-inflammatory activity in the ecteinascidin compounds. Such compounds have been widely described, and may have the following general formula (I): wherein: R5 is OH, alkoxy or alkanoyloxy; R6 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R12 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R16 is hydrogen, alkyl, alkenyl, alkynyl or aryl; R17 is OH, alkoxy or alkanoyloxy; R18 is OH, alkoxy or alkanoyloxy; R21 is H, OH, CN or another nucleophilic group; and Ra is hydrogen and Rb is optionally substituted amino, or Ra with Rb form a carbonyl function ?O, or Ra, Rb and the carbon to which they are attached form a tetrahydroisoquinoline group.

Abstract: Dehydrodidemnin B with useful biological activity has formula (1).

Abstract: The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors.

Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an aryloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.

Abstract: The invention provides antitumour compounds of formula (I), wherein R1 is an aromatic substituent; R2 is hydrogen or a substituent when the dotted line is absent, or R2 is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R2 and the carbon which bears R3; R3 is an oxo group ?O when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R2 and the carbon bearing R3; R4 is hydrogen or a substituent; and pharmaceutically acceptable salts thereof.

Abstract: Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease with avoiding toxicity and leading to clinical improvement.

Abstract: The invention provides variolin derivatives of formula (I), wherein: R1 and R2 are each independently selected from the group consisting of H, OH, OR, SH, SR, SOR, SO2R, NO2, NH2, NHR, N(R)2, NHCOR, N(COR)2, NHSO2R, CN, halogen, C(?O)H, C(?O)R, CO2H, CO2R, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl, C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; and R3 is selected from the group consisting of H, OH and OMe; wherein the or each group R is independently selected from the group consisting of OH, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl, C2-C12 alkynyl, substituted or unsubstituted aryl, substituted unsubstituted aralkyl, substituted or unsubstituted arylalkenyl and substituted or unsubstituted heteroaromatic, and wherein the group R1, R2 or R3 is a group of formula N(R)2 or N(COR)2, each of the R groups may be the same or different, or the two R groups, together with the nitrogen atom to which they are attached, m

Abstract: rDNA corresponding to an endosymbiotic bacteria associated with Ecteinascidia turbinata has been identified. The bacterium appears to be responsible for the biosynthesis of ecteinascidin compounds. The 16S rDNA sequence corresponding to Candidatus Endoecteinascidia frumentensis SEQ ID NO: 1 has been deposited in GeneBank with the accession number AY054370.

Abstract: Et 743 is used in the preparation of a medicament for the treatment of the human body for cancer.